CLINICAL TRIALS LIST
January 1, 2012
BREAST PROTOCOLS
Breast In Situ
Breast Neoadjuvant
SWOG S0800: A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (NAB-Paclitaxel) (NSC-736631) with or without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) plus Pegfilgrastim (Peg-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/NEU Negative Breast Cancer
Breast Adjuvant
NSABP B -47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel plus Cyclophosphamide or Four Cycles of Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Breast Metastatic
SWOG S0500: A Randomized Phase III Trial to Test the Strategy of Changing Therapy versus Maintaining Therapy
for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
NCCTG N1031: Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer
*******Companion Study*******
NCCTG N0392: Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials
Breast Advanced
CALGB 70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer (BREAST, PROSTATE, and MULTIPLE MYELOMA)(repeat)
HEAD AND NECK PROTOCOLS
(None)
LUNG PROTOCOLS
ECOG E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (¡Ý4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC)
Pharm H3E-US-S130: Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer of Nonsquamous Histology. (Eli Lilly)
COLON - RECTAL PROTOCOLS
INST 3304C: A Phase II Trial of Using Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Patients with Newly Diagnosed Resectable Rectal Cancer.
ECOG E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced,K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
NSABP P -5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
RENAL - BLADDER PROTOCOLS
(None)
PANCREAS PROTOCOLS
INST 0802: Phase II trial of combination irinotecan, oxaliplatin and cetuximab for patients with locally advanced or metastatic pancreatic cancer
PROSTATE PROTOCOLS
CALGB 90203: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
ECOG E2809: Phase II, Randomized Study of MK-2206 Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
CALGB 70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer (BREAST, PROSTATE, and MULTIPLE MYELOMA)(repeat)
LYMPHOMA PROTOCOLS
(None)
MYELOMA PROTOCOLS
CALGB 70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer (BREAST, PROSTATE, and MULTIPLE MYELOMA)(repeat)
SARCOMA PROTOCOLS
(None)
MELANOMA PROTOCOLS
(None)
OTHER PROTOCOLS
CALGB 70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer (BREAST, PROSTATE , and MULTIPLE MYELOMA) listed in all three categories
INST 96144: Molecular Genetics Studies in Cancer Patients and Their Families (City of Hope)
NCCTG N0392: Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials
